Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa

B. F. Issell, G. R. Prout, M. S. Soloway, K. B. Cummings, G. Brannen, R. Veenema, M. Flanagan, Norman L Block, J. L. Summers, E. A. Levin

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50% or greater reduction in measured tumor mucosal involvement was obtained in 68% of patients. Forty-two percent of the patients achieved a complete response, and this included 50% of patients with Grade III disease and 70% of patients with a T1 tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3+ months. Fifty-five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose-limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12% of patients.

Original languageEnglish
Pages (from-to)1025-1028
Number of pages4
JournalCancer
Volume53
Issue number5
StatePublished - Apr 26 1984

Fingerprint

Thiotepa
Mitomycin
Urinary Bladder Neoplasms
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Issell, B. F., Prout, G. R., Soloway, M. S., Cummings, K. B., Brannen, G., Veenema, R., ... Levin, E. A. (1984). Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer, 53(5), 1025-1028.

Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. / Issell, B. F.; Prout, G. R.; Soloway, M. S.; Cummings, K. B.; Brannen, G.; Veenema, R.; Flanagan, M.; Block, Norman L; Summers, J. L.; Levin, E. A.

In: Cancer, Vol. 53, No. 5, 26.04.1984, p. 1025-1028.

Research output: Contribution to journalArticle

Issell, BF, Prout, GR, Soloway, MS, Cummings, KB, Brannen, G, Veenema, R, Flanagan, M, Block, NL, Summers, JL & Levin, EA 1984, 'Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa', Cancer, vol. 53, no. 5, pp. 1025-1028.
Issell BF, Prout GR, Soloway MS, Cummings KB, Brannen G, Veenema R et al. Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer. 1984 Apr 26;53(5):1025-1028.
Issell, B. F. ; Prout, G. R. ; Soloway, M. S. ; Cummings, K. B. ; Brannen, G. ; Veenema, R. ; Flanagan, M. ; Block, Norman L ; Summers, J. L. ; Levin, E. A. / Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. In: Cancer. 1984 ; Vol. 53, No. 5. pp. 1025-1028.
@article{dea0467714294d2191e82e2c151ec384,
title = "Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa",
abstract = "Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50{\%} or greater reduction in measured tumor mucosal involvement was obtained in 68{\%} of patients. Forty-two percent of the patients achieved a complete response, and this included 50{\%} of patients with Grade III disease and 70{\%} of patients with a T1 tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3+ months. Fifty-five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose-limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12{\%} of patients.",
author = "Issell, {B. F.} and Prout, {G. R.} and Soloway, {M. S.} and Cummings, {K. B.} and G. Brannen and R. Veenema and M. Flanagan and Block, {Norman L} and Summers, {J. L.} and Levin, {E. A.}",
year = "1984",
month = "4",
day = "26",
language = "English",
volume = "53",
pages = "1025--1028",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa

AU - Issell, B. F.

AU - Prout, G. R.

AU - Soloway, M. S.

AU - Cummings, K. B.

AU - Brannen, G.

AU - Veenema, R.

AU - Flanagan, M.

AU - Block, Norman L

AU - Summers, J. L.

AU - Levin, E. A.

PY - 1984/4/26

Y1 - 1984/4/26

N2 - Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50% or greater reduction in measured tumor mucosal involvement was obtained in 68% of patients. Forty-two percent of the patients achieved a complete response, and this included 50% of patients with Grade III disease and 70% of patients with a T1 tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3+ months. Fifty-five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose-limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12% of patients.

AB - Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50% or greater reduction in measured tumor mucosal involvement was obtained in 68% of patients. Forty-two percent of the patients achieved a complete response, and this included 50% of patients with Grade III disease and 70% of patients with a T1 tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3+ months. Fifty-five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose-limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12% of patients.

UR - http://www.scopus.com/inward/record.url?scp=0021360669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021360669&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 1025

EP - 1028

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -